Covid-19 India Update, June 3: Active cases rise to 4,026; Delhi, Kerala and Gujarat among worst-hit states
By Aditya Bhagchandani Published on June 3, 2025, 12:38 IST
India's total number of active Covid-19 cases rose to 4,026 on June 3, marking an increase of 65 cases in the last 24 hours, according to data released by the Ministry of Health and Family Welfare. During this period, the country also reported five more Covid-related deaths, taking the cumulative death toll to 37 since January 1, 2025. Delhi reports 393 active cases, up by 90
Delhi remains one of the most affected regions, reporting 393 active Covid-19 cases as of June 3 — a sharp spike of 90 cases in just 24 hours. The capital also saw 124 patients recover during the same period. No new deaths were reported in the state. Kerala, Maharashtra, Gujarat remain under close watch
Kerala continues to lead the country in total active cases with 1,416 infections, although the state saw 171 recoveries in the last 24 hours. One new Covid death was recorded — an 80-year-old male patient with multiple comorbidities.
Maharashtra reported 494 active cases, with 12 new cases and 69 recoveries in the last 24 hours. Two new Covid-related deaths were also confirmed.
Gujarat followed closely with 397 active cases, up by 59 from the previous day. The state recorded 36 recoveries and one death. Southern and Eastern states see mixed trends
Karnataka reported 311 active cases — up by 58 in a single day — and recorded four Covid deaths in total so far. Tamil Nadu's active caseload jumped by 26 to reach 215, with one more Covid-linked death being reported. West Bengal's active cases surged by 41 to reach 372, and one additional death was recorded.
Meanwhile, Eastern and Northeastern states like Bihar, Odisha, and Assam saw a minor rise in cases, with no deaths reported. Recoveries continue at a steady pace
India saw 512 new recoveries in the last 24 hours, with the cumulative number of recovered/migrated cases since January 1 reaching 2,700. Covid deaths rise to 37 in 2025
The latest five deaths have been reported from Kerala (1), Maharashtra (2), Tamil Nadu (1), and West Bengal (1). All individuals had pre-existing health conditions such as diabetes, hypertension, and cardiac issues.
Authorities continue to monitor the situation closely and urge citizens to follow basic preventive measures, particularly the elderly and immunocompromised.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Measles exposure sites now include Denver, Glendale, Windsor grocery stores: List
DENVER (KDVR) — Officials are warning of new potential measles exposure sites in Colorado as cases continue to spread following an out-of-state traveler who passed through the Denver International Airport and a nearby hotel last month. A second vaccinated adult in Denver County has tested positive for measles, according to the Colorado Department of Public Health and Environment. The infected individual was onboard the Turkish Airlines flight 201, which arrived at DIA on Tuesday, May 13. Measles vaccination rates drop after COVID-19 pandemic in counties across the US Officials say the infected individual is recovering at home. This marks the seventh case linked to an out-of-state traveler who flew while infectious. So far, officials have learned of four passengers on the flight who were infected and three people who were at the airport during the exposure period on May 14 who are also infected. Measles is highly contagious and can spread through the air via coughs and sneezes. The disease can remain in the air up to two hours after the person has left. The best way to protect yourself and loved ones is through the measles, mumps and rubella vaccine, according to CDPHE. 'In rare cases, people who are vaccinated can still get measles, but their symptoms are usually milder, and they are less likely to spread it to others,' CDPHE explained in a release. Two doses of the MMR vaccination are about 97% effective in preventing measles, CDPHE has repeatedly stated. Here's where health officials say that individuals may have been exposed to measles from the most-recently confirmed measles case of the Denver County resident. Anyone who was there should monitor for symptoms for 21 days after exposure and avoid public gatherings or high-risk settings. Location Date/time When symptoms may develop Trader Joe's661 Logan CO 80203 Thursday, May 299:30 – 11:40 a.m. Through June 19 King Soopers1520 Main St Windsor, CO 80550 Friday, May 3010:30 a.m. – 1:15 p.m. Through June 20 Target4301 E. Virginia CO 80246 Monday, June 29:20 – 11:50 p.m. Through June 23 However, there are exposure locations in Aurora, Colorado Springs, Denver, Evergreen, Glendale, Grand Junction, Greenwood Village and Windsor. All locations and time frames have been listed on CDPHE's website here. Symptoms of measles typically develop seven to 21 days after exposure. Anyone who was at the above locations during the exposure window and develops symptoms should immediately contact their health provider by phone. If you do not have a provider, call urgent care or an emergency department and explain your measles exposure. Calling ahead helps limit further exposures. Data: Map shows which Colorado school districts are most protected from measles CDPHE told FOX31 in February that prior to 2025, the last confirmed case of measles in the state was reported in December 2023, and that most of the time, measles cases occur in Colorado after travel or in under-vaccinated communities. About 93.7% of Colorado children have the MMR vaccination, which protects against measles, mumps, rubella and varicella. That's below the goal threshold of 95% for community immunity. Coloradans can check their own or their child's immunization records through the state's Immunization Information System public portal. If your provider has not reported vaccines, some records may be incomplete. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
35 minutes ago
- Yahoo
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partnership with the Diagnostic Support Unit (UNADIG), a non-profit laboratory of the Oswaldo Cruz Foundation (FIOCRUZ), one of Brazil's leading scientific institutions, to support public health in the country. MGI's first scientific collaboration with UNADIG was established during the COVID-19 pandemic. With the MGISP-960 extractor equipment from MGI, UNADIG was able to process more than 3 million samples from across the country during this period. With the end of the pandemic, UNADIG expanded its portfolio and included different methodological platforms in its laboratory facilities (chemiluminescence, Elisa, photometry, immunoturbidimetry, and indirect potentiometry), as well as genetic sequencing. The new agreement between UNADIG and MGI will enable maintain the molecular tests (RT-PCR) but advances in DNA-based testing. UNADIG has two large high-processing laboratories. The the Clinical Diagnostic Laboratory (DCLIN) has a daily processing capacity of around 29,000 samples, and the Molecular Diagnostic Laboratory (DIMOL) can process between 9,000 and 15,000 RT-PCR samples. In 2025, with the sequencing support of MGI, a process in molecular genetics will begin with the capacity to process over 2,000 samples weekly for the diagnosis of infectious, genetic, and main types of cancer (breast, ovarian, colorectal and prostate), in addition of individual gene sequencing for sporadic or hereditary cancers. "The goal of this collaboration is to help transform healthcare delivery, with a focus on efficiency and accessibility, as it will contribute to expanding access for the Brazilian population to high-complexity laboratory tests with greater speed and reduced costs. This will accelerate the diagnosis and treatment of oncological and epidemiological diseases, strengthening the country's response to outbreaks and epidemics", Carlos Carpio, Senior Commercial Director of MGI Latin America and General Manager for Brazil, explains. To expand its operational and analytical capacity for sample and test processing, UNADIG has acquired state-of-the-art equipment from MGI, including 14 units MGISP-960 nucleic acid extractor; 1 unit MGISP-100 automated genomic library preparation system; 2 units DNBSEQ-G400 and 1 unit DNBSEQ-T7 sequencers; and 1 unit ZTRON platform for genomic data storage and analysis. These technologies also ensure greater speed and accuracy in processing, while enhancing sample handling safety and reducing the risk of contamination. "Precision medicine brings significant benefits to patients and to the public health system, enabling early diagnoses, more effective treatments and the optimization of clinical protocols. This results in cost savings, waste reduction and greater effectiveness of tests and therapies. MGI's equipment, which allows automated processes, helps us achieve these goals", Erika Martins de Carvalho, General Coordinator of UNADIG-RJ of the Vice Presidency of Health Production and Innovation at Fiocruz, says. Increasing the presence in Brazil With the goal of making genetic sequencing more accessible, efficient and scalable through comprehensive solutions, MGI has been expanding its operations in Brazil. In 2024, the company inaugurated a Customer Experience Center in São Paulo, created to offer clinical laboratories and healthcare institutions a dedicated space for hands-on demonstrations. The center aims to enhance technical training and familiarity with MGI's technologies. Highly qualified professionals lead certified training sessions, presentations, evaluations and provide local support for new applications. Also in 2024, MGI established partnerships with Dasa, Grupo Sabin and Oncoclínicas&Co to expand the use of genetic sequencing in Brazil through the adoption of advanced technologies for genetic testing aimed at diagnosing cancers, rare diseases and other conditions, strengthening personalized medicine in the country. About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partnership with the Diagnostic Support Unit (UNADIG), a non-profit laboratory of the Oswaldo Cruz Foundation (FIOCRUZ), one of Brazil's leading scientific institutions, to support public health in the country. MGI's first scientific collaboration with UNADIG was established during the COVID-19 pandemic. With the MGISP-960 extractor equipment from MGI, UNADIG was able to process more than 3 million samples from across the country during this period. With the end of the pandemic, UNADIG expanded its portfolio and included different methodological platforms in its laboratory facilities (chemiluminescence, Elisa, photometry, immunoturbidimetry, and indirect potentiometry), as well as genetic sequencing. The new agreement between UNADIG and MGI will enable maintain the molecular tests (RT-PCR) but advances in DNA-based testing. UNADIG has two large high-processing laboratories. The the Clinical Diagnostic Laboratory (DCLIN) has a daily processing capacity of around 29,000 samples, and the Molecular Diagnostic Laboratory (DIMOL) can process between 9,000 and 15,000 RT-PCR samples. In 2025, with the sequencing support of MGI, a process in molecular genetics will begin with the capacity to process over 2,000 samples weekly for the diagnosis of infectious, genetic, and main types of cancer (breast, ovarian, colorectal and prostate), in addition of individual gene sequencing for sporadic or hereditary cancers. "The goal of this collaboration is to help transform healthcare delivery, with a focus on efficiency and accessibility, as it will contribute to expanding access for the Brazilian population to high-complexity laboratory tests with greater speed and reduced costs. This will accelerate the diagnosis and treatment of oncological and epidemiological diseases, strengthening the country's response to outbreaks and epidemics", Carlos Carpio, Senior Commercial Director of MGI Latin America and General Manager for Brazil, explains. To expand its operational and analytical capacity for sample and test processing, UNADIG has acquired state-of-the-art equipment from MGI, including 14 units MGISP-960 nucleic acid extractor; 1 unit MGISP-100 automated genomic library preparation system; 2 units DNBSEQ-G400 and 1 unit DNBSEQ-T7 sequencers; and 1 unit ZTRON platform for genomic data storage and analysis. These technologies also ensure greater speed and accuracy in processing, while enhancing sample handling safety and reducing the risk of contamination. "Precision medicine brings significant benefits to patients and to the public health system, enabling early diagnoses, more effective treatments and the optimization of clinical protocols. This results in cost savings, waste reduction and greater effectiveness of tests and therapies. MGI's equipment, which allows automated processes, helps us achieve these goals", Erika Martins de Carvalho, General Coordinator of UNADIG-RJ of the Vice Presidency of Health Production and Innovation at Fiocruz, says. Increasing the presence in Brazil With the goal of making genetic sequencing more accessible, efficient and scalable through comprehensive solutions, MGI has been expanding its operations in Brazil. In 2024, the company inaugurated a Customer Experience Center in São Paulo, created to offer clinical laboratories and healthcare institutions a dedicated space for hands-on demonstrations. The center aims to enhance technical training and familiarity with MGI's technologies. Highly qualified professionals lead certified training sessions, presentations, evaluations and provide local support for new applications. Also in 2024, MGI established partnerships with Dasa, Grupo Sabin and Oncoclínicas&Co to expand the use of genetic sequencing in Brazil through the adoption of advanced technologies for genetic testing aimed at diagnosing cancers, rare diseases and other conditions, strengthening personalized medicine in the country. About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
